CNBC March 24, 2025
Ashley Capoot

Key Points

– 23andMe filed for Chapter 11 bankruptcy protection in Missouri federal court on Sunday night.

– Anne Wojcicki has resigned from her role as chief executive effective immediately, though she will remain a member of the board.

– The filing comes after a turbulent period for the genetic testing company, where it has struggled to generate recurring revenue, failed to stand up viable businesses and suffered a cyberattack.

Embattled genetic testing company 23andMe, once valued at $6 billion, filed for Chapter 11 bankruptcy protection in Missouri federal court on Sunday night.

The company’s CEO, Anne Wojcicki, has resigned from her role as chief executive effective immediately, though she will remain a member of the board. Joseph Selsavage, 23andMe’s...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Big pharma’s grip on health care: time for change
GLP-1s are accelerating spending growth on traditional drugs, Evernorth research finds
GLP-1s outpace specialty drug spend for the first time: Report
Continuous Process Improvement: The Secret to Navigating Early-Phase Drug Development
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

Share This Article